Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Safe and Apparently Efficacious But Does
Robert M Cooper1, Adeel Shahzad, James McShane
1Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool, L14 3PE, United Kingdom. robcooper@doctors.org.uk.
Insights
Alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) shows good aggregate results, improving symptoms and reducing left ventricular outflow tract gradients. However, individual outcomes vary, highlighting the need for improved patient selection and procedural refinement.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) presents a significant challenge in managing left ventricular outflow tract (LVOT) obstruction.
- Alcohol septal ablation (ASA) is an interventional technique aimed at reducing LVOT gradients in HOCM patients.
Purpose of the Study:
- To evaluate the individual and aggregate clinical and hemodynamic outcomes of patients undergoing ASA for HOCM.
- To assess the safety and efficacy of ASA in a United Kingdom tertiary referral center.
Main Methods:
- Retrospective case series of 88 patients undergoing ASA between 2000 and 2012.
- Analysis of symptomatic (New York Heart Association class) and hemodynamic (LVOT gradient) responses.
- Assessment of complications, including complete heart block and need for repeat procedures.
Main Results:
- Significant improvement in NYHA class (2.8 to 1.9, P<.001) in 71% of patients.
- Successful reduction of LVOT gradient in 82% of patients (99.8 to 23.8 mm Hg, P<.001).
- Overall successful outcome (symptomatic and gradient) in 66%; 17% experienced complete heart block; 27% required multiple procedures.
Conclusions:
- ASA is a relatively safe procedure for HOCM with few major complications.
- While aggregate outcomes are favorable, individual patient results can vary significantly.
- Refinement in case selection, procedural planning, and technique is crucial for optimizing patient outcomes.
Aims:
To describe individual and aggregate outcomes for patients undergoing alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM).
Methods:
Retrospective case series reviewing all patients undergoing ASA at a United Kingdom tertiary referral center from 2000-2012. Aggregate and individual outcomes are described in terms of symptomatic and hemodynamic response.
Results:
Eighty-eight patients were reviewed. Alcohol was delivered in 84, with clinical status data available in 82 and hemodynamic data available in 74. All patients had resting or exercise stress left ventricular outflow tract (LVOT) gradient >50 mm Hg. Mean age was 60.3 ± 14.3 years. Follow-up period was 4.2 ± 3.3 years. Twenty-four patients (27%) required ≥2 procedures. Complete heart block was observed in 17%. New York Heart Association (NYHA) class pre ASA was 2.80 ± 0.46, improving to 1.92 ± 0.84 post ASA (P<.001). Fifty-eight out of 82 patients (71%) had improved NYHA class. Resting peak gradient was 99.80 ± 45.86 mm Hg. Post-ASA peak gradient fell to 23.77 ± 41.87 mm Hg (P<.001). Sixty-one out of 74 patients (82%) had successful treatment of LVOT gradient. A successful outcome in both symptomatic and gradient treatment was seen in 66% of patients. No patient who received alcohol suffered sudden cardiac death. Fifteen patients had implantable cardioverter defibrillator implantation; no appropriate therapy was delivered.
Conclusions:
ASA is safe, with few major complications. Aggregate outcomes are good, but can hide individual failure. There is a need to refine case selection, procedure planning, and performance to secure more uniform favorable outcomes.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:26Mitral Stenosis III: Medical Management
01:30Cardiomyopathy II: Dilated Cardiomyopathy